|
Clinical Trials for Soft Tissue Sarcoma |
|
|
|
Exploratory safety study of an intravenous infusion of a novel therapeutic agent for the treatment of melanoma, osteosarcoma, soft tissue sarcoma or squamous cell carcinoma in dogs: A multi-center study
Eligibility Requirements
To qualify for enrollment in this study, dogs must have:
• Histologic or cytologic diagnosis of cancer (biopsy or needle aspirate)
• There is at least 1 tumor (melanoma, osteosarcoma, soft tissue sarcoma, or squamous cell carcinoma) which can be measured (minimum 1 cm in diameter);
• Generally feeling well (i.e. eating, drinking, ambulating on their own, etc.)
• No evidence of an active bacterial infection requiring antibiotics (other than topical medications) in the past 7 days;
• No anti-cancer therapy within the past 21 days. This includes chemotherapy, radiation therapy, prednisone (or other forms of corticosteroids), and immunotherapy; No tumors where abscess (infection) would result in major symptoms
Study Objective
The primary objective of this multi-institutional exploratory study is to describe the safety and efficacy of three dosages of an intravenous infusion of C. novyi-NT spores, with and without concomitant therapy, in dogs with spontaneous tumors.
Compensation
The study sponsor will pay for therapeutic agent, diagnostic tests, and follow-up evaluations. In the event that side effects are noted and attributed to the therapeutic agent, the study will pay for medical management of the side effects. Please click on the link for more details.
Location of Trial
Columbus, OH
More information
A Funded Clinical Trial for Dogs with Soft Tissue Sarcoma
Eligibility Requirements
• Client-owned pet dogs;
• Informed owner consent prior to initiation of screening/treatment;
• Measurable soft tissue sarcoma (must have at least 1 target lesion ≥ 1cm longest diameter based on physical exam or ≥ 2cm if measured via thoracic radiographs);
• Histological diagnosis of a Grade II or III soft tissue sarcoma (historical biopsies are accepted), excluding hemangiosarcoma;
• Favorable Performance Score 0-1 (based on Modified Eastern Cooperative Oncology Group Performance Score);
Study Objective
Clinical trial to evaluate a novel form of antiangiogenic therapy in dogs with measurable soft tissue sarcoma.
Compensation
Study drug, diagnostic tests, and follow-up exams will be paid for by the study sponsor. In the event that side effects are noted and attributed to the study drug, the study will pay for medical management of the side effects
Location of Trial
Click link below for current locations nationwide
More information
Analysis of Palladia Pharmacokinetics and Pharmacodynamics at Non-Label Dosing
Eligibility Requirements
• Have a sarcoma, carcinoma, melanoma or other solid tumor (excluding histiocytic sarcoma and hemangiosarcoma) that has either failed standard therapy or for which the owner declines standard therapy
• Have a life expectancy of approximately 90 days
• Have completed any chemotherapy or radiation therapy at least 2 weeks prior to enrollment
Study Objective
The goal of this study is to determine the pharmacokinetics (blood levels) of Palladia given to dogs with cancer at doses lower than that recommended on the label.
Compensation
Palladia will be provided at no cost during, and 6 months after the completion of the study representing a savings of $1500-3000 to owners. The owner is responsible for all other costs including office visits and bloodwork. Please click on the link for more details.
Location of Trial
Columbus, Ohio
More information
Phase I Clinical Trial of Vinorelbine in Tumor- Bearing Cats
Eligibility Requirements
• Cats with any cytologically or histologically confirmed cancer are eligible.
• They may have measureable or microscopic disease to participate.
• They may have had prior surgery, radiotherapy. and/or chemotherapy. However, there must be at least a four week lapse between any of these treatments and entry into the trial.
• Cats may not receive non-steroidal anti-inflammatory drugs (NSAIDS) or steroids while in the study and must undergo a 72 hours washout period if on NSAIDS or steroids prior to stduy initiation.
• They must have normal organ and bone marrow function and have an expected survival of at least 4 weeks.
• Owners must sign a consent form.
Study Objective
To determine the dose-limiting toxicity and maximum tolerated dosage, to establish a safe starting dosage, and to elucidate treatment-related side effects of Vinorelbine in tumor-bearing cats.
Compensation
ost of intial tests, chemotherapy and follow-up CBC will be reimbursed if the cat qualifies for the study.Assuming the cat tolerates the dosage well, treatments may be continue every other week, off-study, at the owners expense. Complications of chemotherapy will NOT be covered by the study. Please click on link for more details.
Location of Trial
Athens, GA
More information
Radiation therapy + local hyperthermia in canine soft tissue sarcomas
Eligibility Requirements
• Dogs must have macroscopic tumor (10cm3-400cm3) (undifferentiated sarcoma, fibrosarcoma, hemangiopericytoma, neurofibrosarcoma, myxosarcoma and liposarcoma)
• A peripherally located tumor with no bone invasion
• Be free of other major medical problems
Study Objective
To evaluate the impact of differing hyperthermia dosing regimens and radiation therapy in canine soft tissue sarcomas.
Compensation
Fully funded
Location of Trial
Raleigh, NC
More information
Canine soft tissue sarcoma study
Eligibility Requirements
• Dogs diagnosed with the following types of soft tissue sarcomas: fibrosarcomas, hemangiopericytomas, peripheral nerve sheath tumors, liposarcomas, leiomysarcomas, rhabdomyosarcomas, myxosarcomas and undifferentiated sarcomas.
Study Objective
The study goal is to identify a gene or protein “signature” to identify those tumors most likely to metastasize, and ultimately to improve the outcome for dogs with soft tissue sarcomas. Dr. Marlene Hauck is evaluating the genetic changes that are seen in soft tissue sarcomas that metastasize versus ones that do not.
Compensation
There is no financial incentive to take part in this study. Please click on link for more details.
Location of Trial
Raleigh, NC
More information
Use of indocyanin green (ICG) and an intraoperative spectroscopy and imaging system (ISIS) in dogs with soft tissue sarcoma (STS)
Eligibility Requirements
• Dogs with biopsy confirmed STS of any histologic subtype
• Tumors must be located on the dog’s trunk to allow surgical excision of at least 3cm around the edges of the tumor, as per standard surgical procedure.
• Prior treatment is acceptable, but a measurable mass must be present at time of study entry
• Dogs must be free of other server underlying disease.
Study Objective
The objective of this study is to evaluate the ability of the ISIS device to assess tumor margins in surgical specimens after they have been removed.
Compensation
This study is partially funded. Please click on link for more details.
Location of Trial
Athens, GA
More information
Phase Ib study of GS-424044 in dogs with malignant neoplasia
Eligibility Requirements
• Dogs with advanced solid tumors (mainly carcinomas and sarcomas)
• Dogs with tumor type confirmed by histology (for solid tumors)
• Dogs must weigh at least 10.0kg
• Dogs must be otherwise healthy and at least one year of age.
• Have adequate organ function as specified by standard laboratory tests
Study Objective
The purpose of this study is to investigate a new chemotherapy drug as treatment for dos with malignant tumors.
Compensation
This study is partially funded. Please click on link for more details.
Location of Trial
Athens, GA
More information
Liposomal clodronate in canine cancer (excluding mast cell tumor, hemangiosarcoma and malignant histiocytosis)
Eligibility Requirements
• Dogs with biopsy-confirmed cancers (excluding mast cell tumor, hemangiosarcom and malignant histiocytosis) are potentially eligible
• The tumor must be less than 8cm (approximately 3.5 inches) in diameter and located in an easily accessible area for biopsy.
• Dogs must have good function of liver and kidneys and acceptable blood cell counts.
• Dogs must be free of underlying disease.
• OWNERS MUST CONSENT TO A POSTMORTEM EXAM (AUTOPSY) AT THE TIME THEIR PET DIES OR IS EUTHANIZED.
Study Objective
The goals of this study are to demonstrate liposomal clodronate as a safe and effective cancer therapy and to determine the anti-tumor activity of liposomal clodronate against a variety of canine tumors.
Compensation
This study is partially funded. Please click on link for more details.
Location of Trial
Fort Collins, CO
More information
Canine patients with osteosarcoma, lymphoma, or oral malignant melanoma, mast cell tumors, soft tissue sarcomas/histiocytic sarcoma/malignant histiocytosis, primary pulmonary cancer, hemangiosarcomas
Eligibility Requirements
• Requirements vary for each type of cancer listed above. Please click on link for more details.
Study Objective
The goal of the CCOGC and UC Davis will be to populate the Pfizer-CCOGC Biospecimen Repository with diseased tissues and specific normal tissues from dogs with cancer over the next three years.
Compensation
This study is partially funded. Please click on link for more details.
Location of Trial
Davis, CA: More Information
North Grafton, MA: More Information
Madison, WI: More Information
Satraplatin for any tumor, including lymphoma
Eligibility Requirements
• Any tumor, including lymphoma confirmed by histopathology or cytology
Study Objective
To determine efficacy of using Satraplatin for various types of cancer using 5mg/m2 daily (orally).
Compensation
This study is partially funded. Please click on link for more details.
Location of Trial
Columbia, MO
More information
IL-12 gene therapy for enhancing therapeutic efficacy of Bleomycin against oral tumors
Eligibility Requirements
• Dogs must have a histopathological diagnosis of oral SCC, oral melanoma or acanthomatous ameloblastona
• Dogs with local or regional but not systemic metastatic disease are eligible for treatment
• Dogs with anticipated survival time without treatment of more than 2 months
• Dogs CANNOT have any history of clinically significant hepatic and/or renal toxicity.
Study Objective
The objective of this study is to evaluate the clinical response of canine oral SCC, oral melanoma or acanthomatous ameloblastoma treated with combination IL-12 and Bleomycin electrochemotherapy vs. Bleomycin electrochemotherapy or IL-12 electrochemotherapy alone.
Compensation
This study is fully funded if you go to LSU. This study is partially funded if you pursue treatment at VOHC. Please click on LSU link for more details.
Location of Trial
Baton Rouge, LA: More information
Norwalk, CT: More information
|
| |
|
